Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGenetic & Molecular TestingCapital Bluecross genetic testing FH Coverage Upda…
    Ask Trek AI about this page
    CurrentCapital BluecrossPolicy MP 2.363

    Genetic testing for heterozygous familial hypercholesterolemia (FH)

    Customize your policy alerts

    Sign up for Capital Bluecross Policy MP 2.363 alerts

    Get alerted when Policy MP 2.363 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs when genetic testing to confirm heterozygous familial hypercholesterolemia is considered medically necessary or investigational for members covered by Capital Bluecross; it addresses index cases, testing of children of affected parents, and testing of adult relatives. Applies to programs and products administered by Capital Bluecross as noted.

    Policy Summary
    PayerCapital Bluecross
    PolicyGenetic testing for heterozygous familial hypercholesterolemia (FH)
    Policy CodePolicy MP 2.363
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewMar 5, 2026
    Next Review DateMay 14, 2025
    Key ActionEnsure documentation shows the individual is in an 'uncertain' diagnostic category and that alternative treatment options are considered before ordering genetic testing.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1:200–1:500estimated prevalence of heterozygous FH
    60%–80%LDLR proportion
    >=90%penetrance
    1500+

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    LDLR pathogenic variants
    Vendor managedManagement change noted
    MP 2.363Policy number

    Coverage Criteria

    inv-01: Medically necessary: index cases for specialty medication eligibility

    Genetic testing to confirm FH considered medically necessary when ALL of the following are met:

    Index case testing for definitive medication eligibility: Genetic testing is targeted to individuals who are in an uncertain category according to clinical criteria (personal and family history, physical exam, lipid levels) and a definitive diagnosis is required as an eligibility criterion for specialty medications (see Policy Guidelines).see Policy Guidelines for definitions of 'uncertain' (e.g., Dutch Lipid Clinic, Simon-Broome, MEDPED)

    Alternative treatment considerations must be in place for individuals with an uncertain diagnosis and a negative genetic test.

    inv-02: Medically necessary: pediatric testing when parental pathogenic variant known

    Genetic testing of children:

    Testing children of affected parents: Genetic testing of children is medically necessary when a pathogenic variant is present in a parent AND general lipid screening is not recommended based on age or other factors.presence of a pathogenic parental variant

    Genetic counseling recommended and should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

    inv-03: Investigational / Not medically necessary

    Not covered / investigational situations:

    Investigational: other uses: Genetic testing to confirm heterozygous FH is considered investigational in all other situations not meeting the specified medically necessary criteria due to insufficient evidence of improved health outcomes.N/A

    Genetic testing of adults who are close relatives of individuals with FH to determine future risk of disease is considered investigational except when performed as part of a formal cascade screening program with demonstrated effectiveness.

    Routine screening of adult close relatives of an index familial hypercholesterolemia (FH) case is unlikely to improve outcomes because management is generally driven by measured lipid levels rather than a genetic label. Screening of relatives may be beneficial when performed as part of a coordinated cascade screening program that systematically identifies and tests at-risk relatives, but outside of such formal programs routine genetic screening of adult relatives is considered investigational.

    The policy administrative record notes that the Benefit Variations Section was removed on 07/22/2025. No explicit exclusions or alternate benefit language relevant to coverage decisions appear in the referenced policy sections after that administrative update.

    Genetic testing of adults who are close relatives of individuals with FH to determine future risk of disease is considered investigational. The policy states there is insufficient evidence to conclude that such testing improves health outcomes when performed outside of specific, effective cascade screening programs.

    Within the document sections referenced there are no explicit statements using the phrase 'not medically necessary.' Administrative updates and the policy history document changes such as removal of the Benefit Variations Section and vendor management, but do not add explicit 'not medically necessary' language in these chunks.

    Covered Indications

    inv-23: Index case genetic testing when clinical diagnosis is uncertain and a definitive genetic diagnosis is required for eligibility for specialty medications.

    Index case genetic testing when clinical diagnosis is uncertain and a definitive genetic diagnosis is required for eligibility for specialty medications.

    Index case testing when clinical criteria inconclusive: Index-case genetic testing is indicated when standardized clinical diagnostic tools place the individual in an 'uncertain' category (examples include Dutch Lipid Clinic scores 3–7 or Simon-Broome probable FH) and a definitive genetic result is required to meet eligibility for specialty therapies such as PCSK9 inhibitors.Refer to Policy Guidelines for Dutch Lipid Clinic, Simon-Broome, MEDPED definitions

    Alternative treatment options must be documented for individuals with an uncertain clinical diagnosis who test negative genetically.

    inv-24: Pediatric testing when a pathogenic variant is present in a parent and routine lipid screening is not recommended by age.

    Pediatric testing when a pathogenic variant is present in a parent and routine lipid screening is not recommended by age.

    Eligibility Requirements

    Testing is targeted to individuals who fall into an 'uncertain' diagnostic category as determined by clinical data including personal and family history, physical exam findings, and lipid measurements. Examples of 'uncertain' include Dutch Lipid Clinic scores of 3–7 (probable/possible), Simon-Broome presentations that do not meet definitive criteria, or cases where MEDPED criteria do not classify an individual as definitive FH. Documentation supporting the uncertain diagnostic status should be available to justify testing.

    Provider Actions & Operational Notes

    Prior Authorization

    Product/program applicability and potential prior authorization

    This policy applies only to certain Capital Blue Cross programs and products and may be subject to benefit variations; prior authorization requirements depend on the member's specific product line (see product variations/FEP note).

    Prior Authorization

    Prior authorization managed by vendor

    As of the retirement review (03/05/2026), the service is to be managed by a vendor; prior authorization requirements may now be handled through that vendor rather than directly through Capital BlueCross processes.

    Note

    Therapy context for testing

    Management of FH is guided primarily by LDL levels and standard lipid therapies (e.g., statins, ezetimibe, PCSK9 inhibitors); genetic testing is used in the context of management when a definitive genetic diagnosis is required for eligibility for specialty medications.

    Coding & Clinical Thresholds

    Coding changes / additionsmixed
    No codes listed
    Dutch Lipid Clinic Criteria score
    Definitive (Dutch Lipid Clinic)Score >= 8
    Probable/Possible (Dutch Lipid Clinic)Score 3–7
    Scoring basisPoints assigned for family history, personal CAD, physical exam signs, LDL levels, and genetic testing (positive genetic test = 8 points)
    Simon-Broome cholesterol threshold
    Adult cholesterol threshold (Simon-Broome)Total cholesterol > 290 mg/dL
    Adult LDL threshold (Simon-Broome)LDL cholesterol > 190 mg/dL
    Diagnostic context

    Definitions

    Uncertain diagnosis of FH
    When to use 'Uncertain'Applied when formal diagnostic criteria do not meet thresholds for a definitive FH diagnosis (e.g., Dutch Lipid Clinic scores 3–7)
    Examples of uncertain categoriesSimon-Broome probable FH (cholesterol threshold plus family history) and cases not meeting MEDPED definitive criteria
    Implication for testingIndividuals in the 'uncertain' category may be candidates for genetic testing to clarify diagnosis
    Familial hypercholesterolemia (FH)
    DefinitionInherited disorder characterized by elevated LDL cholesterol and increased risk of atherosclerotic cardiovascular disease
    Clinical featuresMarkedly elevated LDL, family history, physical signs (e.g., tendon xanthomas), and premature coronary artery disease

    Not Covered / Investigational

    Genetic testing to confirm heterozygous FH is considered investigational in situations other than the policy’s listed medically necessary indications. In particular, testing adult relatives for future risk is considered investigational when not conducted as part of a formal cascade screening program. Requests for testing outside specified criteria may be denied.

    The referenced policy history and administrative sections do not list specific tests or clinical indications as explicitly 'not covered' within these chunks.

    Background

    Familial hypercholesterolemia (FH) is an inherited disorder characterized by markedly elevated low-density lipoprotein (LDL) cholesterol and an increased risk of premature atherosclerotic cardiovascular disease. Heterozygous FH is relatively common (estimated about 1:200–1:500) and diagnosis relies on lipid measurements, family history, physical signs, and formal diagnostic criteria. Genetic testing can identify pathogenic variants in genes such as LDLR, APOB, and PCSK9 and is used primarily to confirm diagnosis when clinical criteria are uncertain or to test children when a pathogenic parental variant is known.

    Policy Summary
    PayerCapital Bluecross
    PolicyGenetic testing for heterozygous familial hypercholesterolemia (FH)
    Policy CodePolicy MP 2.363
    Change TypeNo material change
    Effective DateJul 1, 2026
    Last ReviewMar 5, 2026
    Next Review DateMay 14, 2025
    Key ActionEnsure documentation shows the individual is in an 'uncertain' diagnostic category and that alternative treatment options are considered before ordering genetic testing.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsEligibility RequirementsProvider Actions & Operational NotesCoding & Clinical ThresholdsDefinitionsNot Covered / InvestigationalBackground
    Pediatric targeted testing: Genetic testing of a child is medically necessary when a pathogenic variant has been identified in a parent and routine lipid screening is not recommended based on the child’s age or other clinical considerations.presence of a parental pathogenic variant

    Genetic counseling is recommended and should be provided by a clinician with expertise in genetic medicine; consider guideline-based pediatric lipid screening recommendations.

    inv-25: Genetic testing to confirm a diagnosis of familial hypercholesterolemia or assess future risk when criteria are met (historical policy intent).

    Genetic testing to confirm a diagnosis of familial hypercholesterolemia or assess future risk when criteria are met (historical policy intent).

    Historical statement: The original policy intent (established 06/01/2018) stated that genetic testing to confirm FH or assess future risk of disease may be considered medically necessary when specified criteria are met.See current policy criteria for applicability

    Referenced in policy history; current coverage is governed by the active criteria above.

    Step Therapy

    Step therapy requirements

    No step therapy requirements are specified in these document sections.

    Documentation Required

    Required documentation to justify testing

    Documentation to justify testing should demonstrate that the individual is in an 'uncertain' diagnostic category per clinical criteria (personal and family history, physical exam, lipid levels, or formal tools such as Dutch Lipid Clinic, Simon-Broome, or MEDPED) and that alternative treatment considerations exist for those with uncertain diagnosis and negative genetic testing.

    Documentation Required

    Documentation note

    Policy history and consensus review activity are documented in the policy history, but these sections do not state additional explicit provider documentation requirements.

    Denial Risk

    Investigational status outside listed indications

    Genetic testing to confirm heterozygous FH is considered investigational in all situations other than the specified medically necessary indications and requests outside those criteria may be denied.

    Denial Risk

    Vendor management may affect authorization

    The policy notes that the service is managed by a vendor; failure to follow the vendor's management or authorization process may result in administrative denial or redirection of authorization.

    Documentation Required

    Offer formal genetic counseling

    Formal genetic counseling is recommended in most cases when genetic testing for an inherited condition is considered; providers should offer or coordinate counseling with someone experienced in genetic medicine to assist with interpretation and informed decision-making.

    • Genetic counseling helps patients understand benefits, harms, and familial implications of testing.
    • Counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.
    Note

    Counseling referenced in literature but not mandated

    Although the literature cited references genetic counseling and its importance, the policy text does not impose an explicit pre- or post-test counseling requirement as a condition of coverage.

    Documentation Required

    Coordinate with genetics professionals when ordering

    The policy recommends coordination with genetics professionals—ordering providers should involve or coordinate with individuals experienced in genetic medicine when arranging testing.

    • Ordering providers are expected to coordinate genetic counseling and interpretation with qualified genetics professionals.
    • The policy does not specify a required ordering provider specialty.
    Note

    No specific ordering-provider qualifications specified

    The policy does not specify required qualifications for the ordering provider (e.g., specialist vs primary care); no explicit ordering-provider restrictions are stated in the cited sections.

    Definite diagnosis requires cholesterol threshold plus physical findings (e.g., tendinous xanthoma) or positive genetic test; probable diagnosis uses cholesterol threshold plus family history
    MEDPED example threshold
    MEDPED example (age 20, no family history)Total cholesterol >= 270 mg/dL
    MEDPED example (age 25, first-degree relative with FH)Total cholesterol >= 240 mg/dL
    MEDPED basisRelies on combination of total cholesterol, age, and family history; provides yes/no diagnosis rather than possible/probable categories
    Role of genetic testingGenetic testing may identify pathogenic variants (e.g., LDLR, APOB, PCSK9) to confirm causative variant